EUVIMEDObjevte EUVIMED
Crossref

Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing

Christine S Wolesensky iD, Neha Patel iD, Santosh Nagaraju iD, Steve Hanish, Morgan Roberts, Margaret Dorsett, David J Taber iD

Clinical Transplantation · 2025-11 · 39 (11)

DOI: 10.1111/ctr.70363 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2025-10-31. Written by Christine S Wolesensky and 6 co-authors. Institution: Department of Pharmacy, Medical University of South Carolina, Charleston, South Carolina, USA. Major MEDLINE topics: Tacrolimus, Immunosuppressive Agents, Graft Rejection, Kidney Transplantation. Cited 4 times so far (Crossref); 14 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The aim of this study was to assess the impact of CYP3A5 genotype‐based LCP tacrolimus (tac) versus weight‐based dosing among adult kidney transplant recipients. This was a retrospective longitudinal matched cohort analysis. From February 2021 to June 2023, LCP tac was dosed using standard weight‐based dosing. Starting in June 2023, genotype‐based dosing was used; 148 patients were included (74 in each arm). Baseline characteristics were well balanced between the groups, except for age (control 46 ± 14 vs. 52 ± 14 years, p < 0.01); 32% were females, 36% were African American, 84% were living donors, 40% had DM, and 10% had DGF. At 90‐days post‐txp, the genotype guided cohort had an average of two fewer tacrolimus dose adjustments per patients (4 vs. 6, p < 0.0001), spent longer time in therapeutic range (59% vs. 47%, p = 0.004), and less time in concerning range (9% vs. 18%, p < 0.0001). Acute rejection, de novo donor specific antibodies, and eGFR was similar between the two cohorts. This matched cohort analysis assessing a genotype‐based dosing algorithm demonstrated improved LCP tac dosing efficiency. Patients on average, needed two fewer dose adjustments, spent longer time in therapeutic range and had significantly less time in concerning range.

Subjects

MeSH terms (MEDLINE)

TacrolimusImmunosuppressive AgentsGraft RejectionKidney TransplantationAlgorithmsCytochrome P-450 CYP3AKidney Failure, ChronicHumansFemaleMaleMiddle AgedRetrospective StudiesGenotypeFollow-Up StudiesGraft SurvivalPrognosisAdultRisk FactorsGlomerular Filtration RateDose-Response Relationship, DrugBody WeightDrug MonitoringLongitudinal Studies

Author keywords

kidney transplantmedication dosingmedication safetypharmacogenomicstacrolimus dosing

Substances

TacrolimusImmunosuppressive AgentsCytochrome P-450 CYP3ACYP3A5 protein, human

Authors and institutions

  • Department of Pharmacy, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Deaprtment of Transplant Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID profiles: Christine S Wolesensky, Neha Patel, Santosh Nagaraju, David J Taber

Cite

APA

Wolesensky, C. S., Patel, N., Nagaraju, S., Hanish, S., Roberts, M., Dorsett, M., & Taber, D. J. (2025). Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing. Clinical Transplantation, 39(11). https://doi.org/10.1111/ctr.70363

Vancouver

Wolesensky CS, Patel N, Nagaraju S, Hanish S, Roberts M, Dorsett M, et al. Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing. Clinical Transplantation. 2025;39(11). doi:10.1111/ctr.70363

BibTeX
@article{Wolesensky2025,
  author = {Wolesensky, Christine S and Patel, Neha and Nagaraju, Santosh and Hanish, Steve and Roberts, Morgan and Dorsett, Margaret and Taber, David J},
  title = {Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing},
  journal = {Clinical Transplantation},
  year = {2025},
  volume = {39},
  number = {11},
  doi = {10.1111/ctr.70363}
}
Start for free →